{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:37:42Z","timestamp":1793047062898,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000945","name":"The Pittsburgh Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.schres.2026.06.016","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:39:20Z","timestamp":1781800760000},"page":"248-252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Moderators of behavioral activation versus treatment as usual effects on negative symptoms in patients with Schizophrenia Spectrum Disorder"],"prefix":"10.1016","volume":"295","author":[{"given":"Stephen F.","family":"Smagula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye-Seul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunbyeol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith L.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ferrarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kee-Hong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.schres.2026.06.016_bb0005","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/schbul\/sbq068","article-title":"Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions","volume":"36","author":"Barch","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2026.06.016_bb0010","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.3389\/fpsyg.2016.01759","article-title":"Motivational and behavioral activation as an adjunct to psychiatric rehabilitation for mild to moderate negative symptoms in individuals with schizophrenia: a proof-of-concept pilot study","volume":"7","author":"Choi","year":"2016","journal-title":"Front. Psychol."},{"issue":"7","key":"10.1016\/j.schres.2026.06.016_bb0015","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1080\/10503307.2023.2197630","article-title":"Individual behavioral activation in the treatment of depression: a meta analysis","volume":"33","author":"Cuijpers","year":"2023","journal-title":"Psychother. Res."},{"issue":"3","key":"10.1016\/j.schres.2026.06.016_bb0020","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.euroneuro.2012.04.019","article-title":"Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial","volume":"23","author":"Galderisi","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2026.06.016_bb0025","first-page":"2024","article-title":"Negative symptoms and social cognition as mediators of the relationship between neurocognition and functional outcome in schizophrenia","volume":"15","author":"Giordano","year":"2024","journal-title":"Front. Psychol."},{"issue":"5","key":"10.1016\/j.schres.2026.06.016_bb0030","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0272-7358(03)00070-9","article-title":"Contemporary behavioral activation treatments for depression: procedures, principles, and progress","volume":"23","author":"Hopko","year":"2003","journal-title":"Clin. Psychol. Rev."},{"issue":"4","key":"10.1016\/j.schres.2026.06.016_bb0035","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3988\/jcn.2024.0148","article-title":"Behavioral activation and brain network changes in depression","volume":"20","author":"Jung","year":"2024","journal-title":"J. Clin. Neurol."},{"issue":"3","key":"10.1016\/j.schres.2026.06.016_bb0040","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1176\/appi.ajp.20250034","article-title":"Effect size deflation with increasing sample size in adjunctive trials for negative symptoms in schizophrenia: a meta-analysis and meta-regression across mechanisms of action","volume":"183","author":"Kantrowitz","year":"2026","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2026.06.016_bb0045","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/schbul\/sbq059","article-title":"The brief negative symptom scale: psychometric properties","volume":"37","author":"Kirkpatrick","year":"2011","journal-title":"Schizophr. Bull."},{"issue":"11","key":"10.1016\/j.schres.2026.06.016_bb0050","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/sim.5734","article-title":"Discovering, comparing, and combining moderators of treatment on outcome after randomized clinical trials: a parametric approach","volume":"32","author":"Kraemer","year":"2013","journal-title":"Stat. Med."},{"issue":"2","key":"10.1016\/j.schres.2026.06.016_bb0055","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1176\/appi.ajp.2012.12010109","article-title":"The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation","volume":"170","author":"Kring","year":"2013","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.06.016_bb0060","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.schres.2009.09.004","article-title":"Determinants of everyday outcomes in schizophrenia: the influences of cognitive impairment, functional capacity, and symptoms","volume":"115","author":"Leifker","year":"2009","journal-title":"Schizophr. Res."},{"issue":"9657","key":"10.1016\/j.schres.2026.06.016_bb0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.schres.2026.06.016_bb0070","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/BF02354306","article-title":"A new five factor model of schizophrenia","volume":"65","author":"Lindenmayer","year":"1994","journal-title":"Psychiatry Q."},{"key":"10.1016\/j.schres.2026.06.016_bb0075","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1176\/appi.ajp.20251316","article-title":"Finding a medication for negative symptoms in schizophrenia: why so many failures?","volume":"183","author":"Marder","year":"2026","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2026.06.016_bb0080","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1176\/appi.ajp.162.3.495","article-title":"Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up","volume":"162","author":"Milev","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2026.06.016_bb0085","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.schres.2022.12.051","article-title":"Community-based multi-site randomized controlled trial of behavioral activation for patients with negative symptoms of schizophrenia","volume":"252","author":"Oh","year":"2023","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2026.06.016_bb0090","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.schres.2021.08.005","article-title":"Predictors of response to pharmacological treatments in treatment-resistant schizophrenia \u2013 a systematic review and meta-analysis","volume":"236","author":"Sepp\u00e4l\u00e4","year":"2021","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2026.06.016_bb0095","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpsychires.2016.07.005","article-title":"Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder","volume":"81","author":"Smagula","year":"2016","journal-title":"J. Psychiatr. Res."},{"issue":"6","key":"10.1016\/j.schres.2026.06.016_bb0100","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/PSY.0000000000000712","article-title":"Moderators of response to cognitive behavior therapy for major depression in patients with heart failure","volume":"81","author":"Smagula","year":"2019","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.schres.2026.06.016_bb0105","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1176\/appi.prcp.20250178","article-title":"Pilot study of behavioral activation treatment for negative symptoms in older adults with schizophrenia spectrum disorder","volume":"0","author":"Smagula","year":"2026","journal-title":"Psychiatr. Res. Clin. Pract."},{"issue":"8","key":"10.1016\/j.schres.2026.06.016_bb0110","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jagp.2020.04.008","article-title":"Resting state functional connectivity and outcomes of psychotherapies for late-life depression","volume":"28","author":"Solomonov","year":"2020","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2026.06.016_bb0115","first-page":"1075","article-title":"Precision assignment to psychosocial interventions for late-life depression: an automated treatment decision rule","volume":"82","author":"Solomonov","year":"2025","journal-title":"JAMA Psych."},{"issue":"1","key":"10.1016\/j.schres.2026.06.016_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15487768.2013.873370","article-title":"Integrated psychosocial treatment for negative symptoms","volume":"17","author":"Velligan","year":"2014","journal-title":"Am. J. Psychiatr. Rehabil."},{"issue":"11","key":"10.1016\/j.schres.2026.06.016_bb0125","first-page":"1241","article-title":"A novel approach for developing and interpreting treatment moderator profiles in randomized clinical trials","volume":"70","author":"Wallace","year":"2013","journal-title":"JAMA Psych."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996426001994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996426001994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:09:22Z","timestamp":1793045362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996426001994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":25,"alternative-id":["S0920996426001994"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2026.06.016","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Moderators of behavioral activation versus treatment as usual effects on negative symptoms in patients with Schizophrenia Spectrum Disorder","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2026.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}